MedTrace Logo

Immunotherapy for Hepatocellular Carcinoma

NCT06241326 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 11000

Last updated 2024-04-10

No results posted yet for this study

Summary

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

Conditions

Interventions

OTHER

Immunotherapy-based Combination Therapies

immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06241326 on ClinicalTrials.gov